Klaviyo director sells 98,782 shares at ~$20.5
A bona fide gift of 17,885 shares was made to a donor-advised fund, and Hodgkins Trust then held 94,457 shares for Hallen’s benefit.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Klaviyo, Inc. (KVYO) insider Ed Hallen, a director and more than 10% owner, reported indirect dispositions of Series A Common Stock on August 31, 2026, under a Rule 10b5-1 trading plan adopted on June 1, 2026. Entities associated with Hallen sold 98,782 shares in open-market or private transactions at weighted-average prices around $20.47–$20.49 per share and made a bona fide gift of 17,885 shares to a donor-advised fund. After these trades, Hodgkins Trust held 94,457 shares for Hallen’s benefit. The shares are held by Hodgkins Trust and Hodgkins LLC, and Hallen disclaims Section 16 beneficial ownership except to the extent of any pecuniary interest.
Insider Trade Summary 10b5-1
Net Seller: 98,782 shares
Net Sell
3 txns
Insider
Hallen Ed
Role
Director, 10% Owner
Sold
98,782 shs ($2.02M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Series A Common Stock F1, F2, F3 | 39,167 | $20.47 | $802K |
| Sale | Series A Common Stock F1, F4, F5 | 59,615 | $20.49 | $1.22M |
| Gift | Series A Common Stock F6, F5 | 17,885 | $0.00 | $0.00 |
Holdings After Transaction:
Series A Common Stock — 94,457 shares (Indirect, By Hodgkins Trust);
Series A Common Stock — 447,746 shares (Indirect, By Hodgkins LLC)
Footnotes (6)
- F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 1, 2026.
- F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.30 to $20.77 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. Shares are owned directly by Hodgkins Trust for the benefit of the Reporting Person and the Reporting Person's family, and of which the trustee is an independent institution. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.
- F4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.30 to $20.78 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5. Shares held by Hodgkins LLC, of which the Reporting Person serves as manager. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.
- F6. Represents a bona fide gift of 17,885 shares of stock from Hodgkins LLC, of which Reporting Person serves as manager, to a donor-advised fund pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 1, 2026.
Key Figures
Shares sold (total): 98,782 shares
Shares gifted: 17,885 shares
Weighted average sale price (Hodgkins Trust block): $20.47 per share
+5 more
8 metrics
Shares sold (total)
98,782 shares
Aggregate non-derivative sales on August 31, 2026 by entities associated with Ed Hallen
Shares gifted
17,885 shares
Bona fide gift from Hodgkins LLC to a donor-advised fund on August 31, 2026
Weighted average sale price (Hodgkins Trust block)
$20.47 per share
39,167 shares sold; prices ranged from $20.30 to $20.77
Weighted average sale price (Hodgkins LLC block)
$20.49 per share
59,615 shares sold; prices ranged from $20.30 to $20.78
Shares sold by Hodgkins Trust
39,167 shares
Indirectly owned for the benefit of Ed Hallen and his family
Shares sold by Hodgkins LLC
59,615 shares
Indirectly owned through Hodgkins LLC managed by Ed Hallen
Shares held by Hodgkins Trust after transactions
94,457 shares
Indirect holdings following the August 31, 2026 sale from the trust
Rule 10b5-1 plan adoption date
June 1, 2026
Plan under which the reported sales and gift were effected
Key Terms
Rule 10b5-1 trading plan, weighted average price, bona fide gift, Section 16 beneficial ownership, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
bona fide gift financial
"Represents a bona fide gift of 17,885 shares of stock"
A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.
Section 16 beneficial ownership regulatory
"The Reporting Person disclaims Section 16 beneficial ownership of such shares"
donor-advised fund financial
"gift of 17,885 shares of stock from Hodgkins LLC ... to a donor-advised fund"
A donor-advised fund is a charitable giving account that lets an individual or family deposit cash, stock, or other assets now, get an immediate tax benefit, and then recommend grants to charities over time. Think of it like a private charitable bucket you control without running a charity yourself; investors care because it’s a tax-efficient way to give appreciated securities, can change when and how donated shares enter the market, and affects personal and corporate tax planning.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did KVYO director Ed Hallen report on August 31, 2026?
Ed Hallen reported indirect dispositions of 98,782 KVYO shares sold and a 17,885-share bona fide gift of Series A Common Stock on August 31, 2026, through Hodgkins Trust and Hodgkins LLC.
Were Ed Hallen’s KVYO transactions made under a Rule 10b5-1 trading plan?
Yes. The filing states that the reported sales and the bona fide gift were effected pursuant to a Rule 10b5-1 trading plan adopted by Ed Hallen on June 1, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
